Literature DB >> 30298961

Evidence of increased fecal granins in children with irritable bowel syndrome and correlates with symptoms.

Robert J Shulman1, Lena Öhman2, Mats Stridsberg3, Kevin Cain4, Magnus Simrén2, Margaret Heitkemper4.   

Abstract

BACKGROUND: Granins have been implicated in the pathophysiology of irritable bowel syndrome (IBS) in adults. We sought to determine whether fecal granins are altered in children with IBS and associated with symptoms.
METHODS: Children (7-12 years of age) with IBS and healthy controls (HC) kept daily pain and stool diaries for 2 weeks. Stool samples were analyzed for chromogranins A and B (CgA, CgB) and secretogranins II and III (SgII, SgIII). Children also completed psychological measures to assess anxiety, depression, somatization, and internalizing symptoms. KEY
RESULTS: Fecal CgB and SgIII concentrations were higher in all the boys (IBS plus HC, n = 48) than in all the girls (IBS plus HC, n = 75) (P = 0.02 and P = 0.046, respectively). CgA and SgIII were greater in children with IBS (n = 52) vs HC (n = 69) (P = 0.01, P = 0.017, respectively). CgB and SgII did not differ between groups. In children with IBS, the number of pain episodes per week and mean daily pain rating correlated positively with all four granins. The number of stools per day correlated positively with CgB and SgII, and the percent of diarrheal stools (6 or 7 on the Bristol Scale) correlated inversely with all four granins in boys but not in girls. Fecal granins did not correlate with psychological measures. CONCLUSIONS AND INFERENCES: As measured by fecal granins, there is evidence of neuroimmune activation in children with IBS. Granins are related to abdominal pain symptoms, stooling frequency, and stool form in children with IBS. Sex influences the fecal concentration of CgB and SgIII.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  children; chromogranin; irritable bowel syndrome; pediatric; secretogranin

Mesh:

Substances:

Year:  2018        PMID: 30298961      PMCID: PMC6296885          DOI: 10.1111/nmo.13486

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  53 in total

1.  Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome.

Authors:  Magdy El-Salhy; Tanisa Patcharatrakul; Jan Gunnar Hatlebakk; Trygve Hausken; Odd Helge Gilja; Sutep Gonlachanvit
Journal:  Scand J Gastroenterol       Date:  2017-03-27       Impact factor: 2.423

2.  Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children.

Authors:  E Olafsdottir; L Aksnes; G Fluge; A Berstad
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

3.  Inhibitory influence of chromogranin A N-terminal fragment (vasostatin-1) on the spontaneous contractions of rat proximal colon.

Authors:  Antonella Amato; Angelo Corti; Rosa Serio; Flavia Mulè
Journal:  Regul Pept       Date:  2005-08-15

4.  Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.

Authors:  Mirjana Rajilić-Stojanović; Elena Biagi; Hans G H J Heilig; Kajsa Kajander; Riina A Kekkonen; Sebastian Tims; Willem M de Vos
Journal:  Gastroenterology       Date:  2011-08-05       Impact factor: 22.682

5.  Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome.

Authors:  Magdy El-Salhy; Bjarne Lomholt-Beck; Trygve Hausken
Journal:  Scand J Gastroenterol       Date:  2010-07-06       Impact factor: 2.423

6.  Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.

Authors:  M Stridsberg; K Oberg; Q Li; U Engström; G Lundqvist
Journal:  J Endocrinol       Date:  1995-01       Impact factor: 4.286

7.  Functional Disorders: Children and Adolescents.

Authors:  Jeffrey S Hyams; Carlo Di Lorenzo; Miguel Saps; Robert J Shulman; Annamaria Staiano; Miranda van Tilburg
Journal:  Gastroenterology       Date:  2016-02-15       Impact factor: 22.682

8.  The effect of a chromogranin A-derived peptide (CgA4-16) in the writhing nociceptive response induced by acetic acid in rats.

Authors:  Jean-Eric Ghia; Francis Crenner; Marie-Hélène Metz-Boutigue; Dominique Aunis; Fabielle Angel
Journal:  Life Sci       Date:  2004-08-27       Impact factor: 5.037

9.  Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity.

Authors:  Hans Strid; Magnus Simrén; Anders Lasson; Stefan Isaksson; Mats Stridsberg; Lena Öhman
Journal:  J Crohns Colitis       Date:  2013-05-18       Impact factor: 9.071

Review 10.  Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?

Authors:  Patrick A Hughes; Heddy Zola; Irmeli A Penttila; L Ashley Blackshaw; Jane M Andrews; Doreen Krumbiegel
Journal:  Am J Gastroenterol       Date:  2013-05-07       Impact factor: 10.864

View more
  3 in total

1.  Multiple psychological factors predict abdominal pain severity in children with irritable bowel syndrome.

Authors:  John M Hollier; Miranda A L van Tilburg; Yan Liu; Danita I Czyzewski; Mariella M Self; Erica M Weidler; Margaret Heitkemper; Robert J Shulman
Journal:  Neurogastroenterol Motil       Date:  2018-12-13       Impact factor: 3.598

2.  Human-centered approaches that integrate sensor technology across the lifespan: Opportunities and challenges.

Authors:  Teresa M Ward; Marjorie Skubic; Marilyn Rantz; Allison Vorderstrasse
Journal:  Nurs Outlook       Date:  2020-07-04       Impact factor: 3.250

3.  Activation of the Innate Immune System in Children With Irritable Bowel Syndrome Evidenced by Increased Fecal Human β-Defensin-2.

Authors:  Robert J Shulman; Sridevi Devaraj; Margaret Heitkemper
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-20       Impact factor: 13.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.